Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87257 | 0.83 | — | — | |
| Methyl Alcohol SCHEMBL10396919 | 0.81 | LMNA (0.41) | SLC1A3SLC1A2SLC1A1LMNAPARP10 | |
| SCHEMBL5495 | 0.81 | CYP1A2 (0.40) | SLC1A3SLC1A2SLC1A1LMNAPARP10 | |
| SCHEMBL12259 | 0.81 | — | — | |
| SCHEMBL7739283 | 0.81 | CYP1A2 (0.40) | SLC1A3SLC1A2SLC1A1LMNAPARP10 | |
| SCHEMBL5252 | 0.81 | CYP1A2 (0.40) | SLC1A3SLC1A2SLC1A1LMNAPARP10 | |
| SCHEMBL11224706 | 0.81 | CYP1A2 (0.40) | SLC1A3SLC1A2SLC1A1LMNAPARP10 | |
| SCHEMBL7738618 | 0.81 | CYP1A2 (0.40) | SLC1A3SLC1A2SLC1A1LMNAPARP10 | |
| SCHEMBL5244 | 0.78 | — | — | |
| Bicarbonate SCHEMBL9406595 | 0.78 | LMNA (0.41) | SLC1A3SLC1A2SLC1A1LMNAPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019216294-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | 日本新薬株式会社 (JP) | 2019-11-14 | — | — | WO | disclosed |